Bridging The Pharma Divide: A Comparative Study of Jan Aushadhi Kendras and Private Pharmacies in India

India’s pharmaceutical retail sector is undergoing a structural shift, driven by the government-backed Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP) and the entrenched dominance of private pharmacies. This paper presents a comparative analysis of Jan Aushadhi Kendras (JAKs) and private pharmacies across three dimensions—pricing, reach, and compliance—during 2024–2025. Using government reports, industry data, and secondary literature, the study finds that JAKs consistently provide medicines at 50–90% lower prices than branded equivalents, generating substantial out-of-pocket savings and reducing catastrophic health expenditures. Their rapid expansion, with over 15,000 outlets nationwide, has narrowed the urban–rural access gap, particularly in aspirational districts. Compliance mechanisms at JAKs are more centralized and stringent, requiring WHO-GMP certified suppliers and batch-level testing, though both channels face systemic challenges of drug quality and consumer trust. Private pharmacies, while unmatched in absolute reach and urban convenience, continue to operate with higher price points and more fragmented oversight. The findings highlight JAKs’ transformative role in advancing pharmaceutical equity, while underscoring persistent challenges in quality assurance, last-mile accessibility, and public perception. The study concludes that India’s path to universal, affordable, and trustworthy access to medicines will depend on strengthening regulatory oversight, expanding digital compliance systems, and intensifying awareness campaigns to build confidence in generics. This study employs a comparative, mixed-methods approach to evaluate Jan Aushadhi Kendras (JAKs) and private pharmacies in India.